Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
about
Phosphodiesterases and cardiac cGMP: evolving roles and controversiesEfficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog.Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium.African traditional medicines for erectile dysfunction: elusive dream or imminent reality?Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.Enhancing cognition before clinical symptoms of dementia.Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.The effects of tadalafil on renal ischemia reperfusion injury: an experimental study.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancerCinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsNitric oxide/redox-based signalling as a therapeutic target for penile disorders.Neurorestorative treatment of stroke: cell and pharmacological approaches.Chronic sildenafil in men with diabetes and erectile dysfunction.Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury.Phosphodiesterase 5 inhibitors: are they cardioprotective?Therapeutic angiogenesis for coronary artery disease: clinical trials of proteins, plasmids, adenovirus and stem cells.Clinical and molecular genetics of the phosphodiesterases (PDEs).Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].An evaluation of vardenafil as a calcium channel blocker in pulmonary artery in ratsModulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate.Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium.Dual regulation of the ATP-sensitive potassium channel by caffeine.Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives.Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxideOpening of Ca2+-activated K+ channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice.Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits.Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte.Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.
P2860
Q27692588-8958A427-A3CC-4A63-97F9-16B0B68C9B03Q33153631-D5545F79-1151-4E0F-A2F0-63BF06B2A9A3Q33552229-E23BA0A1-E6DB-4AC8-8A96-90212E808F39Q33966155-58122E65-0163-45D7-88F3-763D57C5CB3CQ34091110-A34F95D4-3946-4D9E-9DD4-71EDFC57F05BQ34220033-84541BE9-2D7C-41D6-AD5E-FA2C9916DEEBQ34252901-E663B315-B021-4C6F-87B8-B0A425534E5FQ34357737-6631522F-900C-4649-A602-A93678ACF2CDQ34708103-9D1450B2-1BC8-4D08-B87C-C17FB8409DA7Q34793299-25063D62-F314-456D-9440-147123495D31Q34984650-AC273A5F-4464-4DA0-90A2-731640A69D96Q35184655-D083E6B1-85DF-4B2F-8CDE-172F68DAEF25Q35827798-D0BE8204-F383-4B0D-8AF3-7074AD6EA319Q35850118-0AAB15B1-33EC-4CAB-B98C-DF3FCEED7674Q36357896-C5BFC7D1-6ECB-4B1D-A167-A70C5344DC43Q36460566-F400D91C-552A-4656-9A33-2106A000E17FQ36481074-592F55E2-90D1-49B6-A4D0-236E116B30F2Q36608810-CC6DF166-4C0D-4E98-91E7-8C3A1EEEA00FQ36835843-2A5326B1-5A5C-4A62-A86D-07930DD9648EQ37018954-D4DA27B2-B6BF-4E4D-8F88-2F900074C90BQ37230750-5E6C3D70-4FE4-4D34-AD9E-D316C297CA9DQ37264402-183AFA66-054A-44E8-B91D-B2726D1B25E4Q37497840-8EBFCCBA-89AC-4C45-9ED0-14678FA641FFQ37608469-E3DAE105-C249-4356-8346-35EC055631BAQ37657841-68150360-11C6-42F7-8C7E-403EC836C71BQ37696624-A0815D81-702A-4D4F-8956-29E0BEBC22C6Q37971308-E2D0AD95-5070-44EB-B10F-7943ED69FE26Q38721255-E5C394C9-1C57-4ACE-82B3-40FF9745B935Q38760600-D004F841-3999-4A37-8100-B826B13E438BQ39759995-AC9D62AD-5C76-4916-95CA-0576C6977BF1Q40124831-E5828DCB-0C05-4287-91FC-62275AAA583FQ40170511-815BF041-1247-4D10-96E6-448307BA7C67Q41383381-34780432-EAB3-47BA-973D-45C74EF59382Q41819549-CACFAE7D-FBAA-4D83-8AAE-D27F967F5DB5Q42316209-14F67AE3-B7E5-4800-B403-D260B312CD28Q44903215-B93257A1-96E6-4083-9320-7B18FA9DA1A2Q44906320-B6089A19-C19A-4A30-8073-86B57CA920F8Q44907848-C7782DCA-3D77-4ABD-B3F3-17679403FAABQ44924018-28F2CF38-8606-4E8D-B109-01F0FFD87BE9Q44970917-5FA63FB7-E270-43EB-8190-21DA94CFFCE0
P2860
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
@ast
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
@en
type
label
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
@ast
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
@en
prefLabel
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
@ast
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
@en
P2093
P1476
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy
@en
P2093
Fadi Salloum
John Hawkins
Rakesh C Kukreja
Ramzi Ockaili
P304
P356
10.1016/J.YJMCC.2003.11.001
P577
2004-02-01T00:00:00Z